Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 28, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,450,000 Ordinary Shares of 25 pence each.
- Purchase Date: September 28, 2012.
- Price Range: Highest price paid was 1,441 pence per share; lowest price paid was 1,426.5 pence per share.
- Treasury Holdings (Settled): 499,065,427 shares (9.17% of total issued share capital).
- Treasury Holdings (Including Unsettled): 502,615,427 shares (10.16% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,945,193,521 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,450,000 shares. Consequently, the percentage of shares held in Treasury increased to 10.16% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,945,193,521) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the current percentage of voting rights held in Treasury (10.16% including unsettled shares).
- Review the price paid per share (1,426.5 to 1,441 pence) against market prices on September 28, 2012.
- Note that this filing does not contain operational or financial performance data for the quarter.